La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novonesis Bilan de santé

Santé financière contrôle des critères 5/6

Novozymes possède un total de capitaux propres de DKK14.4B et une dette totale de DKK7.4B, ce qui porte son ratio d'endettement à 51.6%. Son actif total et son passif total sont DKK28.4B et de DKK14.0B. L'EBIT de Novozymes est DKK4.5B ce qui fait que son ratio de couverture des intérêts 53.8. Elle dispose de liquidités et de placements à court terme de DKK1.1B.

Informations clés

18.1%

Ratio d'endettement

€1.99b

Dette

Ratio de couverture des intérêts	15.7x
Argent liquide	€260.80m
Fonds propres	€11.01b
Total du passif	€4.25b
Total des actifs	€15.25b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NVZM.F ( DKK9.5B ) dépassent ses passifs à court terme ( DKK7.3B ).

Passif à long terme: Les actifs à court terme de NVZM.F ( €1.8B ) ne couvrent pas ses passifs à long terme ( €2.6B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de NVZM.F ( 15.7% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de NVZM.F a été réduit de 36.2% à 18.1% au cours des 5 dernières années.

Couverture de la dette: La dette de NVZM.F est bien couverte par le flux de trésorerie opérationnel ( 56% ).

Couverture des intérêts: Les paiements d'intérêts de NVZM.F sur sa dette sont bien couverts par l'EBIT ( 53.8 x couverture).

Novonesis Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines